DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vaxart
Vaxart
Vaxart, Inc. Signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow, LP
Vaccine Formulations for Protection Against Covid-19 Infection
Adenoviral Vector-Based Vaccine Platforms for Developing the Next Generation of Influenza Vaccines
Edição Atualizada Em 30/11/2020
The Importance of T-Cell Responses for COVID-19 Vaccines By
Current State and Challenges in Developing Respiratory Syncytial Virus Vaccines
Vaxart Expands Intellectual Property Portfolio with U.S. Patent Allowance
Journal Pre-Proof
Encouraging Vaccine Innovation: Promoting the Development of Vaccines That Minimize the Burden of Infectious Diseases in the 21St Century Report to Congress
Racing Against COVID-19: a Vaccines Strategy for Europe
A Non-Replicating Ad5 Vaccine for the Treatment of HSV-2 Infection
Vaxart's Oral Vaccine Is Room Temperature Stable
Vaccines Innovative
Vaxart's COVID-19 Vaccine Selected for the U.S. Government's Operation
View Complaint
GUIDE to the CORONAVIRUS DRUG PIPELINE CORONAVIRUS OUTBREAK: New Vaccines in the Pipelines of Leading Pharmaceutical Companies
Looking Forward: Vaccine Uptake and Behavior
COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System As a Potential Vaccine Platform
Top View
Covid-19 Thesaurus Covid-19 Thesaurus Version 1.2 (Last Updated: 2021-01-07)
Vaxart's Oral COVID Vaccine Candidate: an Easy Pill to Swallow
Norovirus and Respiratory Syncytial Virus (RSV)
Overview of Vaxart's Oral Vaccine Platform
DRAFT EP201209 Vaxart
Vaxart Announces Creation of New Scientific and Clinical Advisory Board
An Indian Perspective of Some Recent Developments in Polio, DPT, Zika and Rotavirus Vaccines
Pandemic Profiteering
Adenoviral Vector Vaccine Platforms in the SARS-Cov-2 Pandemic ✉ Samir Andrade Mendonça1, Reka Lorincz1, Paul Boucher1 and David T
Vaccine Technology Renaissance Vaxart’S Platform Technology Can Produce Vaccines Against Virtually Any Antigen in the Form of an Oral Pill Rather Than an Injection
Recombinant Antigens/Proteins
Advances in Human Norovirus Vaccine Research
Case 2:20-Cv-01402-GJP Document 68 Filed 09/21/20 Page 1 of 68
Return W:S:S Vaccines
P0386 Oral Adenovirus-Based Quadrivalent Influenza Vaccine
DRAFT Landscape of COVID-19 Candidate Vaccines – 15 October 2020
Vaxart Initiates Clinical Development of First Oral Norovirus Vaccine
Corporate Presentation
Development and Applications of Viral Vectored Vaccines to Combat Zoonotic and Emerging Public Health Threats
New Data from Vaxart Oral COVID-19 Vaccine Phase I Study Suggests Broad Cross-Reactivity Against Other Coronaviruses
Vaxart Flu Press Release 102517 FINAL
ACIP COVID-19 Vaccines Work Group
Abstract Keywords
Environmental Risk Assessment of Recombinant Viral Vector Vaccines Against SARS-Cov-2
Vaxart Initiates Clinical Development of First Oral RSV Vaccine
Operation Warp Speed at Two Months
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
Next-Generation Influenza Vaccines: Opportunities and Challenges
Overview of the Respiratory Syncytial Virus Vaccine Candidate Pipeline in Canada
Kirk Himmelberg, Et Al. V. Vaxart, Inc., Et Al. 20-CV-05949-Class Action
Pre-Clinical Studies of a Recombinant Adenoviral Mucosal Vaccine to Prevent SARS-Cov-2 Infection
A Summary of the SARS-Cov-2 Vaccines and Technologies Available Or Under Development
Master Question List for COVID-19 (Caused by SARS-Cov-2) Weekly Report 29 September 2020
Ra Capital's Covid-19 Map
The Respiratory Syncytial Virus Vaccine Landscape: Lessons from the Graveyard and Promising Candidates